SAR445088

Phase 3Small molecule

SAR445088 is one of 68 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Ulcerative ColitisActive, not recruiting

Cold Agglutinin DiseaseActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Cold Agglutinin DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 3

1 2

Icotyde

Johnson & Johnson

Phase 3

—3

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 4

SHR0302

RReistone Biopharma Company Limited

Phase 3

2 5

Diosmin

TTanta University

Phase 3

1 6

Dexmedetomidine- Ketamine

Pfizer

Phase 3

1 7

SC Golimumab

Merck & Co.

Phase 3

1 8

IV Golimumab

Merck & Co.

Phase 3

1 9

SAR445088

BBioverativ, a Sanofi company

Phase 3

1 10

TA-650

Tanabe Pharma Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed·BBioverativ, a Sanofi company·Phase 2·NCT04658472·98 enrolled

Cold Agglutinin Disease1 trial

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Terminated·BBioverativ, a Sanofi company·Phase 1·NCT04802057·9 enrolled

Ulcerative Colitis1 trial

MANTA-RAy: Filgotinib in Active UC

Completed· Gilead logo

Gilead·Phase 3·NCT04669600·740 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAR445088. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR445088 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR445088. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioverativ, a Sanofi company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioverativ, a Sanofi company

SAR445088

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Cold Agglutinin Disease1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News